Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What would be your post-operative therapy approach for a high grade neuroendocrine carcinoma of the thymus?
What if there was mediastinal nodal involvement?
Answer from: Radiation Oncologist at Academic Institution
Postoperative RT.
Sign in or Register to read more
13071
Related Questions
What CTV expansions do you use for NSCLC with conventional chemoradiation and do you do different expansions based on specific histologies?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
How would you approach SBRT in a pacemaker-dependent elderly patient with Stage I NSCLC whose SBRT plan Dmax exceeds the pacemaker tolerance?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
What clinical and pathologic features do you use to discern whether >= 2 synchronous lung nodules, biopsy proven lung adenocarcinoma, are different primaries versus metastatic disease?
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
How do you counsel patients with Stage IIIA EGFR+ lung cancer regarding treatment intent with concurrent chemoRT + consolidative systemic therapy?
How would you approach an in-field recurrence after lung SBRT for a T1 NSCLC in a patient with poor underlying lung function?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?